Open an account

Immunocore Holdings

IMCR · NASDAQ

$32.60+$2.76 (+9.25%)TodayMarket closed ·
Prev close $29.84

About IMCR

Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. The company is headquartered in Abingdon, Oxfordshire and currently employs 524 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The firm has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.

Employees
524
Headquarters
Abingdon, Oxfordshire
Listed
Feb 5, 2021
Sector
Health Care
Industry
Biotechnology
Website
immunocore.com

IMCR key statistics

Market cap
1.54B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
483.58K
Volume
941.96K
Open price
$30.11
High today
$32.75
Low today
$29.70
52 Week high
$40.71
52 Week low
$27.50

Immunocore Holdings (IMCR) at a glance

Immunocore Holdings (IMCR) last traded at $32.60, with a market cap of 1.54B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $29.70 and $32.75. The current price is 9.8% above the day's low and 0.5% below its high.

Volume so far is 941.96K shares, above the average of 483.58K shares a day.

Over the past year Immunocore Holdings has ranged from $27.50 to $40.71, and now sits 39% of the way up that range.

Immunocore Holdings met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.02 per share against an estimate of $0.0105.

The average analyst price target is $65.93, 102.2% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

63%of 8 analyst ratings say Buy
  • Buy62.5%
  • Hold37.5%
  • Sell0.0%
Price target · 14 analystsAvg $65.93
Low
$34.34
Now
$32.60
High
$95.55

IMCR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 113.5% on average.

  1. Q3 FY24: reported $0.17 per share against an estimate of -$0.3582
  2. Q4 FY24: reported -$0.47 per share against an estimate of -$0.2619
  3. Q1 FY25: reported $0.10 per share against an estimate of -$0.3973
  4. Q2 FY25: reported -$0.20 per share against an estimate of -$0.2006
  5. Q3 FY25: reported $0.00 per share against an estimate of -$0.2664
  6. Q4 FY25: reported -$0.60 per share against an estimate of -$0.2481
  7. Q1 FY26: reported $0.25 per share against an estimate of -$0.2644
  8. Q2 FY26: reported -$0.02 per share against an estimate of $0.0105

IMCR news

  • Immunocore Hldgs Q2 2026 Earnings Call Transcript

  • Press releasePRNewswire

    Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types

  • Press releasePRNewswire

    Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer

  • 'South Africa, Gates Foundation Pledge Funds to Sustain HIV Research After US Cuts' - Bloomberg News

  • Demystifying Immunocore Holdings: Insights From 9 Analyst Reviews

  • Analyst Expectations For Immunocore Holdings's Future

  • Avi Kapoor

    Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday

  • What Analysts Are Saying About Immunocore Hldgs Stock

Similar companies

Companies in the same industry as Immunocore Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.